AI Analysis AI Analysis of GLTO AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add GLTO to Watchlist?
  • Easy Tracking In The Watchlist
PDF

Red day on Friday for Galecto, Inc.
(Updated on Jun 05, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since May 27, 2026 Loss -14.64%

No changes to the price of Galecto, Inc. stock on the last trading day (Friday, 5th Jun 2026). During the last trading day the stock fluctuated 0% from a day low at $21.58 to a day high of $21.58. The price has fallen in 5 of the last 10 days and is down by -12.91% for this period.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -6.03% during the next 3 months and, with a 90% probability hold a price between $15.68 and $24.71 at the end of this 3-month period.

GLTO Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, June 04, 2026, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Galecto, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $23.31 and $24.75. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Galecto, Inc. stock

Galecto, Inc. finds support from accumulated volume at $21.21 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 6.62%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (GLTO) For The Upcoming Trading Day Of Monday 8th

For the upcoming trading day on Monday, 8th we expect Galecto, Inc. to open at $21.58, and during the day (based on 14 day Average True Range), to move between $20.80 and $22.36, which gives a possible trading interval of +/-$1.55 (+/-7.46%) up or down from last closing price. If Galecto, Inc. takes out the full calculated possible swing range there will be an estimated 7.46% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $21.21 (1.71%) than the resistance at $25.00 (15.85%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Galecto, Inc. stock A Buy?

Galecto, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.868 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 8, 2026 - $21.58 ( 0%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

GLTO Performance

Trading levels for GLTO

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 21.58 -
R2 21.58 -
R1 21.58 -
Price 21.58
S1 21.58 -
S2 21.58 -
S3 21.58 -

Accumulated Volume Support & Resistance Levels

Level Price
R3 26.45 22.57%
R2 25.85 19.79%
R1 25.00 15.85%
Price 21.58
S1 21.21 -1.71%
S2 18.78 -12.97%
S3 18.11 -16.08%

FAQ

What is the symbol for Galecto, Inc. Stock and on which exchange is it traded?
The symbol for Galecto, Inc. is GLTO and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Galecto, Inc. Stock?
Galecto, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Galecto, Inc. Stock?
Galecto, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Galecto, Inc. Stock.

What's the current price of Galecto, Inc. Stock?
As of the end of day on the Jun 05, 2026, the price of an Galecto, Inc. (GLTO) share was $21.58.

What is the 52-week high and low for Galecto, Inc. Stock?
The 52-week high for Galecto, Inc. Stock is $38.33 and the 52-week low is $2.46.

What is the market capitalization of Galecto, Inc. Stock?
As of the Jun 05, 2026, the market capitalization of Galecto, Inc. is 34.47M.

When is the next earnings date for Galecto, Inc.?
The upcoming earnings date for Galecto, Inc. is Aug 05, 2026.
Click to get the best stock tips daily for free!
ABOUT GALECTO, INC.
Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a ...
GOLDEN STAR
Ticker Change Signal Date
FISV
0% Nov 30
K
KEEL
0% Nov 30
D
DFTX
0% Nov 30
R
RKLZ
0% Nov 30
R
RKTO
0% Nov 30

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE